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Abstract
Background: Although there have been a number of studies on the pathogenesis of Crimean-Congo hemorrhagic
fever (CCHF) recently, knowledge on this topic is still insufficient. This study aims to reveal the kinetics of serum
CCHF virus (CCHFV) titers, serum levels of anti-CCHFV immunoglobulin (Ig)G, tumor necrosis factor (TNF)-α, interleukin
(IL)-6, IL-10, and interferon (IFN)-γ in CCHF patients.
Methods: In total, 31 CCHF cases (11 fatal) were studied. Serum samples were obtained daily from all patients from the
time of admission and continued for a 7-day hospitalization period for serologic (ELISA), virologic (real-time PCR), and
cytokine (ELISA) analysis.
Results: The mean serum CCHFV titer at admission was 5.5E + 09 copies/mL in fatal cases and 5.7E + 08 copies/mL in
survivors (p < 0.001). Compared to survivors, both the mean serum levels of IL-6 and TNF-α at admission were found to
be significantly increased in fatal cases. The serum levels of IL-6, TNF-α and serum CCHFV titer at admission were
significantly and positively correlated with disseminated intravascular coagulation (DIC) scores (r = 0.626, p = 0.0002;
r = 0.461, p = 0.009; and r = 0.625, p = 0.003, respectively). When the data obtained from the sequential determination
of CCHFV titer and levels of anti-CCHFV IgG, IL-6, TNF-α, IL-10 and IFN-γ were grouped according to the days of illness,
the initial serum CCHFV titer of a fatal patient was 5.5E + 09 (copies/mL) and it was 6.1E + 09 (copies/mL) in a survivor
on the 2 day of illness. While significant alterations were observed in all cytokines during the monitoring period, IL-6
levels remained consistently higher in fatal cases and TNF-α levels increased in both in fatal and non-fatal CCHF cases.
Conclusions: The increased CCHFV load and higher concentrations of IL-6 and TNF-α, the presence of DIC, and
the absence of CCHFV specific immunity are strongly associated with death in CCHF.
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Background
Crimean-Congo hemorrhagic fever (CCHF) is a viral
hemorrhagic fever (VHF) which is caused by an RNA virus,
the CCHF virus (CCHFV), belonging to the Nairovirus
genus of the Bunyaviridae family. The disease transmission
occurs mainly through Hyalomma m. marginatum tick
exposure and it progresses in severe cases resulting in
fever, hemorrhage, shock, and death [1-3]. It has become
an important zoonosis in Africa, Asia and Europe, particu-
larly in Turkey [3,4]. By the year 2012, more than 7000
confirmed CCHF cases were identified in Turkey with a
mortality rate of 5% (unpublished data from the Turkish
Ministry of Health). The disease typically presents itself in
a significant proportion of patients with coagulation disor-
ders, fibrinolysis, petechia, ecchymosis, and uncontrolled
bleeding from the mucosa and puncture sites [2,3,5]. The
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capillary endothelium and mononuclear cells are the two
main targets for CCHF [3,6-8]. Endothelial damage either
may occur directly by invasion of viruses or indirectly due
to chemokines and cytokines released from activated
mononuclear cells [3].
In humans and primates, expression of some inflam-
matory mediators such as IL-6, IL-8, IL-10, TNF-α,
monocyte chemoattractant protein (MCP)-1α, and ni-
trous oxide (NO) are triggered during VHF. Further-
more, when human cells are exposed to VHF agents
in vitro, they may produce many of these inflammatory
mediators. Such inflammatory mediators play an import-
ant role in fatal cases with fulminant progression and in
the development of shock [5]. Previous studies revealed
that serum pro-inflammatory and anti-inflammatory cy-
tokines including TNF-α, IL-6, IL-10, IL-12, and IFN-γ
were increased in patients with CCHF and levels of
some cytokines were higher in the fatal cases than those
were in survivors [9-11]. Likewise, the serum viral titers
have also been studied in CCHF [11-16]. The kinetics of
serum viral load, cytokines and CCHFV-specific anti-
body levels need characterization for a thorough under-
standing of CCHF pathogenesis during the course of the
infection. This study aims to reveal the kinetics of serum
CCHFV load, anti-CCHFV IgG titers and cytokines in-
cluding TNF-α, IL-6, IL-10, and IFN-γ by daily simultan-
eous sequential estimation in patients with CCHF and
analyze their contribution to the pathogenesis of this
disease.
Methods
Study design and patients
This prospective clinical and laboratory study has been
performed in 31 adult CCHF patients (11 fatal, 20 non-
fatal) who were hospitalized and followed-up in the Service
of Infectious Diseases, Cumhuriyet University Hospital,
Sivas, Turkey. The diagnosis of CCHF was confirmed
by real-time PCR. Written informed consent was ob-
tained from all participating CCHF patients or their rela-
tives. This study was approved by the Human Ethics
Committee of Cumhuriyet University.
Serum collection and diagnostic tests for CCHF
Three sets of serum samples were obtained from all
CCHF-suspected patients by venipuncture at admission
and serum sampling with double sets was continued
daily for 6 days (7 days in total). Serologic, virologic and
cytokine (IL-6, IL-10, TNF-α, and IFN-γ) analysis were
implemented wherever possible. One sample obtained
from each patient at admission was sent to the Refik
Saydam Hygiene Institute (RSHM, CCHF reference cen-
ter), Ankara, Turkey for serologic (anti-CCHFV IgM,
ELISA IgM capture assay) and virologic (double antibody
sandwich capture assay) analysis. The reagents used for
these tests were kindly provided by the Centers for
Diseases Control and Prevention (CDC), USA. The
remaining two serum samples from each patient were
stored at -80°C until use. Further sampling of serum
was based on the positive results for serologic (anti-
CCHFV IgM) and/or virologic analysis, which were
obtained from the RSHM within 24 – 48 hrs. Double
sets of serum samples from patients were also stored
at -80°C for cytokine and anti-CCHFV IgG antibody
estimation.
Assays of serum CCHFV titers, anti-CCHFV IgG antibody,
and cytokine levels
At the end of the study and serum collection process,
serum samples were transported on dry ice to the vir-
ology laboratory of Gulhane Military Faculty of Medicine
(GATA), Ankara, Turkey for CCHFV titer estimations. A
one-step real-time reverse transcriptase (RT)-PCR (7500
real time PCR system, Applied Biosystem, Foster, CA,
USA) was used to monitor the viral load, as described in
Yapar, et al. [12] and the results were expressed as copy/
mL. The other serum samples were used to measure
serum cytokine (BioSource® CA, USA) and anti-CCHFV
IgG (Vector-Best Laboratories, Novosibirsk, RU) levels
using ELISA test kits. Each sample was measured in du-
plicate and cytokine levels were expressed as picogram
per milliliter. The serum levels of anti-CCHFV IgG anti-
bodies were expressed as optical density. The sequential
IgG determination could be performed only in 20 (9
fatal) patients due to death of some patients and insuffi-
cient serum samples from others. The cytokine estimation
was done according to the manufacturer’s instructions at
the Cumhuriyet University Medical Faculty Research
Center Class 2 biological safety cabinets and strict barrier
precautions (N95 mask, glow, gown etc.) were used in
both centers during the course of the study.
Diagnostic laboratory tests and patient follow-up
For each patient, complete blood count, blood aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
lactate dehydrogenase (LDH), and creatine phosphokinase
(CPK) levels were measured on a daily basis. Blood urea
nitrogen (BUN), creatinine, albumin, prothrombin time
(PT), activated partial thromboplastin time (aPTT), inter-
national normalized ratio (INR), fibrinogen, fibrin degrad-
ation products and D-dimer were measured every other
day. Double sets of blood cultures, serum C-reactive pro-
tein (CRP) levels (nephelometric method) and erythrocyte
sedimentation rate (ESR) were measured at admission,
and these were repeated when needed. All patients were
also evaluated for brucellosis, viral hepatitis (A, B and C)
malaria, and hematological malignancy suggesting CCHF.
Disseminated intravascular coagulation (DIC) score for
each CCHF patient was calculated according to the
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recommendations of the International Society on Throm-
bosis and Hemostasis (ISTH) scoring system [17]. When
the achieved score was ≥5, the CCHF patient was consid-
ered compatible with DIC [17]. Patients who had a history
of diseases, acute infection, anti-inflammatory drug usage,
pregnancy, a recent diagnosis of diabetes mellitus, viral
hepatitis, brucellosis and those who had negative test re-
sults for CCHF were excluded from the study. All patients
received standard medical care including fluid (crystalloid
or synthetic colloid, intravenously), blood products (single
random donor or apheresis platelet suspensions, fresh fro-
zen plasma, erythrocyte suspensions), cardiovascular, and
respiratory support when needed. All the patients were
followed-up until discharge from the hospital or death.
Statistical analysis
All the demographics, clinical and routine laboratory
data at admission, data obtained from consecutive mea-
surements of serum CCHF titers, cytokine levels, CCHF
serology, other routine laboratory tests, and outcome
data were entered into a statistics program, Statistical
Package for Social Sciences (SPSS Inc. Chicago, IL,
USA). The Mann-Whitney U-test was used for group
comparisons. Categorical variables were compared using
the Chi-square test, although Fisher’s exact test was used
when the data was sparse. In the assessment of the rela-
tions between the variables, Pearson and Spearman correl-
ation coefficients were calculated. Tests were two-tailed
and a difference of p < 0.05 was accepted as statistically
significant. Charts were plotted using GraphPad Prism
v4.0 (GraphPad Software, San Diego, CA, USA). Data
were presented as frequency and percent or mean ± stand-
ard error and (range) as appropriate.
Results
Patient characteristics
In total, 31 CCHF patients (11 fatal; 16 male) were stud-
ied. Close contact with livestock (87.1%), a tick-bite his-
tory (64.5%), and living in the CCHF epidemic area were
the risk factors for having acquired the infection. The
mean age was 53.8 ± 4.5 (25-82) years in the fatal CCHF
group, and 45.9 ± 3.6 (19-81) years in the non-fatal
CCHF group (p > 0.05). The time to hospitalization
after the onset of symptoms was significantly longer in
the non-fatal group than that of fatal group (5.9 ± 0.4
vs. 4 ± 0.4 days; p = 0.011). During the follow-up period,
2 patients died on day 1 of hospitalization, 2 patients
died on day 2, 1 patient each died on days 4, 5, 6, 8, and 9.
Clinical and laboratory findings
Comparison of symptoms and signs between fatal and
non-fatal CCHF patient groups at admission is presented
in Table 1. The blood hemoglobin (12.4 vs. 13.8 g/dl), al-
bumin (2.8 vs. 2.9 g/dL) levels and ESR (27 vs. 21 mm/hr)
were identical between fatal and non-fatal groups (p > 0.05
for all comparisons). Routine tests of blood coagulation,
such as PT and aPTT were revealed coagulation to be sig-
nificantly prolonged and the INR value was significantly
higher in the fatal group when compared to that of the
non-fatal group (PT: 21.7 vs. 14 s, p < 0.001; aPTT: 49.2 vs.
34.2 s, p = 0.001; INR: 1.9 vs. 0.97, p < 0.001). Furthermore,
according to the recommendation of ISTH DIC scoring
system [17], all (100%) fatal, but 5 (25%) survivors had
DIC (p < 0.0001) with the DIC score in the fatal group be-
ing significantly higher than that in the survivors (6.8 vs.
3.2, p < 0.0001). The blood CRP and bilirubin levels were
also found to be significantly higher in the fatal CCHF
patients than that in the survivors (CRP: 46 vs. 6.3 mg/L,
p < 0.001; bilirubin: 1.35 vs. 0.84 mg/dL, p = 0.034).
Serum CCHFV titers and cytokine levels
The CCHFV titers at admission in fatal patients was
found to be significantly higher than that in the non-
fatal patients (5.5E + 09 ± 1.4E + 09 vs 5.7E + 08 ± 3.8E +
08 copies/mL, p < 0.0001). Fatal CCHF cases showed sig-
nificantly higher IL-6 levels than did the patients in the
non-fatal group (326.1 ± 74.9 vs 70.7 ± 17.4 pg/mL; p <
0.001). The serum level of IL-10 was 46.5 ± 9.6 (pg/mL)
in the survivors and it was 30.5 ± 12.8 (pg/mL) in the
fatal group (p > 0.05). The serum level of TNF-α was
found to be 161.3 ± 26.3 (pg/mL) in the fatal group and
77.3 ± 7.2 (pg/mL) in the survivors (p < 0.001). Serum
levels of IFN-γ were comparable between the two groups
(fatal vs survivor, 18.6 ± 8.1 vs 9.9 ± 2.2 pg/mL; p > 0.05).
Table 1 Comparison of the symptoms and signs between
the non-fatal and fatal CCHF patients at admission
Symptoms and
signs, n (%)
All patients Non-fatal Fatal P-value
(n = 31) (n = 20) (n = 11)
Weakness 31 (100) 20 (100) 11 (100) 1.0
Myalgia 29 (93.5) 19 (95) 10 (90) 1.0
Fever 29 (93.5) 18 (90) 11 (100) 1.0
Nausea and/or
vomiting
24 (77.4) 14 (70) 10 (90) 0.37
Chills 23 (74.1) 19 (95) 4 (36.4) 0.0009
Headache 22 (70.9) 12 (83) 10 (90) 0.11
Diarrhea 16 (51.6) 13 (65) 3 (27.2) 0.07
Rash 16 (51.6) 9 (45) 7 (63.9) 0.46
Bleeding 13 (41.9) 7 (35) 6 (54.5) 0.45
Facial hyperemia 10 (32.2) 7 (35) 3 (27.2) 1.0
Petechiae or
ecchymosis
8 (25.5) 4 (20) 4 (36.3) 0.41
Hepatomegaly 4 (12.9) 3 (15) 1 (9.1) 1.0
Jaundice 4 (12.9) 0 (0) 4 (36.3) 0.01
Stupor 1 (3.2) 0 (0) 1 (9.1) 0.003
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Correlation analysis among the cytokines, CCHFV titers
and routine laboratory tests at admission
We found significant positive correlations between serum
IL-6 and blood CRP levels, PT, aPTT, INR values, DIC
scores, and serum TNF-α levels of all CCHF patients (r =
0.489, p = 0.005; r = 0.462, p = 0.009; r = 0.692, p < 0.0001;
r = 0.544, p = 0.0015; r = 0.626, p = 0.0002; and r = 0.356,
p = 0.04, respectively) (Additional file 1: Figure S1(A-F).
In addition, there was also a positive correlation be-
tween serum IL-6 and AST (r = 0.575, p = 0.0007)
levels (Additional file 1: Figure S1G). While no signifi-
cant correlation between serum TNF-α and blood PT,
aPTT and INR values existed, a positive correlation be-
tween serum TNF-α levels and DIC scores was ob-
served (r = 0.461, p = 0.009) (data not shown). Further,
there was no significant correlation between the serum
levels of cytokines studied and the blood platelet
counts. The serum CCHFV titer was significantly and
positively correlated with serum IL-6, TNF-α and
blood CRP levels, PT, aPTT, INR values and DIC scores
(r = 0.809, p < 0.0001; r = 0.510, p = 0.0047; r = 0.540,
p = 0.0027; r = 0.657, p = 0.0001; r = 0.486, p = 0.0075;
r = 0.739, p < 0.0001 and r = 0.625, p = 0.0003, respect-
ively) (Additional file 2: Figure S2A-G).
Kinetics of serum CCHFV titers, anti-CCHFV IgG levels,
selected routine laboratory tests and serum cytokine
concentrations
Data obtained from the analysis of serum samples in the
fatal and the survivor groups were pooled according to
the days of illness and the kinetic changes of serum
CCHFV titers and anti-CCHFV IgG levels (Figure 1), se-
lected routine laboratory tests (Figure 2), and serum
concentrations of the cytokines (IL-6, TNF-α, IL-10 and
IFN-γ), studied (Figure 3) were plotted. The day of onset
of symptoms including fever and/or chills was assumed
to be the first day of illness for each patient.
It was observed that the earliest day of admission
among the patients was the second day of illness (one
patient each in the fatal and in the survivor group). The
initial viral titer in the serum of fatal and non-fatal pa-
tients was 5.5E + 09 and 6.1E + 09 copies/mL, respect-
ively. While CCHFV titers appeared to decline over
time, no clear trend could be recognized in the fatal pa-
tients. A great variation was observed on day 5 of illness;
however, the viral titers remained high, and by day 12
only a 2-log decline was observed from the baseline in
this group of patients. A female CCHF patient, who died
on day 12 of the illness, had a viral titer of 7.4E + 07 cop-
ies/mL on the same day. The viral titers also appeared to
decline over time in the survivors. However, in contrast
to fatal patients, a clear declining trend was observed for
serum viral titers in this group of patients. A male sur-
vivor had a viral titer of 8.1E + 03 copies/mL on day 14
of the illness. An approximate 6-log decline of viral titers
from the baseline was observed in the survivors. In con-
trast to the fatal patients, the serum anti-CCHFV IgG
levels of survivors reached the optic density level of 0.90
(the threshold level by the manufacturer) on day 8 of the
illness and increased rapidly during the monitoring
period. The analysis of two serum samples obtained
from the days 8 and 9 of the illness of a fatal patient who
died on day 15 of illness (9 days after hospitalization)
showed insufficient IgG levels (Figure 1).
When the kinetics of WBC, blood platelet count,
serum AST, ALT, CPK and LDH levels were analyzed
(Figure 2A-F), it was seen that while the blood platelet
count of the survivors reached the normal range on day
11 of the illness, the fatal patients remained thrombocy-
topenic until death. Although great variations were ob-
served on certain days in AST, ALT, and LDH levels in
the fatal patients during the monitoring period, both
liver enzymes and LDH were found to be higher in the
fatal group than in the survivors. Two apparent peaks in
the ALT level were observed on days 5 and 9 of CCHF
in the fatal group. (Figure 2D).
The serum levels of IL-6 in both fatal and non-fatal
groups were found to be increased on day 2 and contin-
ued to increase up to day 4 after the onset of fever in
the fatal group. Great variations were observed on day 4
and 7 and the cytokine level remained highest in this
group of patients. Although variations were determined
on different illness days, the IL-6 levels gradually de-
creased during the convalescence phase and the lowest
level was determined on day 14 in the non-fatal group
(Figure 3A). Interestingly, the serum TNF-α concentra-
tion for both groups of patients was increased in the
acute phase and remained as high by day 14 in the non-
fatal group. A peak concentration with a great variation
for this cytokine was determined on day 5 of CCHF in
fatal patients (Figure 3B). The level of IL-10 gradually
Figure 1 Kinetics of serum virus titers (left y-axis) in logarithmic
scale and CCHFV specific IgG antibodies (right y-axis) by days
of illness in fatal and non-fatal CCHF groups. Data are expressed
as mean ± SE. The threshold optic density value for anti-CCHFV IgG
as indicated by the manufacturer is indicated by a dotted line.
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Figure 2 Kinetics of some routine laboratory analysis on different days of illness in fatal and non-fatal CCHF cases. (A) White blood cells;
(B) Platelets; (C) Aspartate aminotransferase; (D) Alanine aminotransferase; (E) Creatine phosphokinase; and (F) Lactate dehydrogenase. Data are
expressed as mean ± SE.
Figure 3 Kinetics of serum cytokine concentrations over multiple days of illness in fatal and non-fatal CCHF cases. (A) Interleukin-6; (B) Tumor
necrosis factor-alpha; (C) Interleukin-10; and (D) Interferon-gamma. Data are expressed as mean ± SE.
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increased in both groups and peak serum levels were de-
termined on day 4 and 5 in both groups, respectively. In
contrast to the non-fatal group, a low level of IL-10 was
determined on day 5 in the fatal group (Figure 3C). The
IFN-γ level in both groups rapidly increased from day 2
to day 5 and then decreased up to day 11 in the fatal
group and day 13 in the non-fatal group respectively
(Figure 3D).
Discussion
Although the number of studies on CCHF pathogenesis
increased significantly, data in this field are still insuffi-
cient. Therefore, in this study, some of the routine la-
boratory tests, serum cytokines, CCHFV titers and virus
specific IgG antibodies along with their kinetics were in-
vestigated. We observed that some of the routine test
parameters were significantly altered compared to those
of the survivors. We also observed that certain parame-
ters of the survivors progressively improved especially
during the second week of the disease. Our findings are
in agreement with other reports where both leukopenia
and thrombocytopenia are frequently detected in the
CCHF patients [2,3,10,18]. By contrast to the survivors,
prolonged coagulation tests and higher INR values –
both of which were reported to be poor indicators for
CCHF by a previous study [4]- were more common in
the fatal cases. In the fatal CCHF cases, the serum levels
of ALT had two peaks on days 5 and 9 of the disease.
We think that these peaks may have occurred during
the inflammatory response and subsequent hepatocyte
damage, and by direct damage to the hepatocytes by
CCHFV. The positive correlation between IL-6 and the
AST concentration in this study also supports this sug-
gestion. The virus has both hepatotropic and neuro-
tropic characteristics and it has been detected in both
liver and brain tissues in a mouse model [19] and
within the hepatocytes from fatal CCHF cases [7]. Fur-
thermore, the source of the prolonged viremia in a
mouse model was found to be the liver [19]. While
fatal patients had thrombocytopenia, the blood platelet
counts of the survivors started to increase on day 9
and reached the normal range on day 11 of the illness.
We think that development of specific IgG antibodies
against CCHFV in the host results in the symptoms of
the disease subsiding and normalizations of laboratory
test values in the survivors, as shown previously by a
clinical study [20].
Except for IL-10 and IFN-γ, the serum TNF-α and IL-
6 levels were found to be significantly higher for the fatal
cases than were those of the survivors at admission. In
addition, the absence of prominent reductions in the se-
quential determinations of TNF-α in both groups and
IL-6 in fatal group strongly suggests the existence of a
profound inflammatory response in the fatal CCHF cases
and this was evident until death. The results of this
study regarding the cytokine levels in CCHF at admis-
sion are in agreement with previously reported studies
performed on humans [9-11]. It is believed that CCHFV
changes the homeostatic mechanisms in the host through
two different pathways. One of them is a direct effect on
the endothelial cells associated with homeostasis and
platelets and the other one is an indirect effect on the
endothelium via immunological and inflammatory path-
ways [3,21]. In a previous immunohistochemical study,
the virus has been shown in endothelial cells in patients
with CCHF [7]. It is likely that the functional impairment
of the endothelial cells depends on the circulating media-
tors which appear during the acute phase of the disease. It
has previously been shown that cells infected with filo-
viruses release inflammatory mediators including TNF-α
that may disrupt endothelial permeability and integrity
[22]. Subendothelial edema observed in the CCHF pa-
tients is probably associated with TNF-α [23]. Further-
more, TNF-α has anti-fibrinolytic effects by inhibiting the
physiological anticoagulation pathways, and the produc-
tion of plasminogen activators and the plasminogen acti-
vator inhibitor (PAI)-I are induced by this cytokine. These
effects facilitate DIC development in the host. Another
important pro- and anti-inflammatory cytokine, IL-6, is
the actual mediator for the activation of the coagulation
system in the host [24,25]. Furthermore, tissue factor
(TF)-mediated thrombin formation which is initiated by
the IL-6 and TF/activated factor VII complex, has an im-
portant role in the development of DIC, similar to TNF-α
[9,26,27]. In this study 16 (51.6%) out of the 31 patients
(11 fatal, 5 survivors) had DIC at admission and nearly
69% of the 16 patients with DIC died during the follow-up
period. We also observed that the presence of DIC is an
indicator for poor prognosis in patients with CCHF, as
previously described [18,28].
IL-10, a potent anti-inflammatory mediator of vascular
damage, controls coagulation by inhibiting TF expression
on the monocyte surface [29]. It also plays a role in the ef-
ficiency of the humoral immune response by amplification
of Ig secretion by activated B-lymphocytes and in B-cell
differentiation [30]. The exact cause of thrombocytopenia
in VHF has not been demonstrated yet. However, the level
of IL-10 has been found to be significantly correlated with
thrombocytopenia in Ebola virus infection [31]. Moreover,
a fatal CCHF case that had a high level of IL-10 and severe
thrombocytopenia has been defined [9]. In contrast to the
results of this study, fatal Ebola patients had higher serum
IL-10 levels than the survivors [31]. IFN-γ, which is se-
creted by activated T-cells and natural killer (NK) cells, is
responsible for the inflammatory response and viral im-
munity via macrophage activation [32]. In contrast to our
findings, a previous study showed significantly higher
levels of this cytokine in CCHF [11].
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Recent studies indicate that CCHFV titer in serum
samples is important to predict the clinical severity and
the fatal outcome in CCHF [11,13,14]. A clinical study
from Kosovo suggests a viral load of >108 copies/mL as
a strong factor for differentiating CCHF patients who
died from those who survived [13]. Another report from
Turkey showed that viral load ≥109 copies/mL could be
considered to predict a fatal outcome with 88.9% sensi-
tivity and 92.6% specificity [14]. Other studies also re-
vealed that the fatal CCHF cases had a higher blood viral
load [15,16]. In our study, we determined that the ad-
mission serum CCHFV titer in both groups was found
to be higher than the ranges mentioned above. In this
study, we also determined that 8 (72.2/%) out of 11 fatal
and 3 (15%) out of 20 non-fatal CCHF cases had the
virus titer of >108 copies/mL at admission (data not
shown). Furthermore, according to kinetics of serum
CCHFV titers, all but one, of the fatal cases had a virus
titer of >108 copies/mL until death. The observation of
only a 2-log decline in the CCHFV titer from the base-
line in the fatal group might have occurred due to in-
appropriate immune response both in the early and late
phase of the disease in these cases. Innate immunity is
the first line of defense against viruses before adaptive
immunity develops and it is characterized by the pro-
duction of type I IFN, which is crucial for limiting the
early replication and spread of viruses. CCHFV is one of
the viruses sensitive to type I IFN, and it delays the IFN
response [33]. Furthermore, CCHFV challenge of type I
IFN receptor-knockout mice results in a fatal outcome
and higher CCHFV titers [34,35]. This study showed
that all survivors develop a sufficient amount of specific
IgG antibody after 8 days of fever onset. Due to the limi-
tation in serum sample amounts, we could not estimate
IgG antibody levels in the fatal patients after day 9 of
the illness. However, when compared to survivors, the
consistently higher CCHFV titer in a fatal CCHF patient
after day 8 of the illness strongly suggests insufficient
amount of specific IgG antibody against the virus. The ini-
tial virus specific antibody activity can be assessed by ELISA
IgG and IgM after 2 days of the onset of CCHF symptoms
and the levels increase between days 7 to 9 of the illness in
survivors [20]. Likewise Duh, et al. [13] showed that all 9
fatal and most of the severe CCHF cases had no IgG anti-
bodies as determined by ELISA even on day 9 of the illness.
Other reports also suggest insufficient IgG antibody re-
sponses in severe and fatal CCHF cases [15,20,23]. The lack
of specific IgG antibodies in fatal cases has entailed using
human CCHF hyperimmunoglobulin with a promising ef-
fect [16]. Finding a meaningful correlation between serum
CCHFV titer and DIC score can be expected because the re-
sults of this study, as well as earlier ones, suggest a close re-
lationship between CCHFV titer, and both clinical severity
and fatal outcome in CCHF [11,13-16].
Conclusion
In conclusion, the results of this study showed that
higher CCHFV titers and overproduction of TNF-α and
IL-6, (a phenomenon called cytokine storm), the pres-
ence of DIC, and the absence of CCHFV specific im-
munity have important roles in the pathogenesis of
CCHF and are strongly associated with a fatal outcome.
In addition, the levels of serum IL-6, TNF-α, and CCHFV
titers correlated with the existence of DIC, subsequently
leading to hemorrhages and death. Lower serum CCHFV
titers in the survivors than in the fatal patients during the
course of CCHF may suggest that the disease is being
controlled both in the acute and convalescent phases
by the innate and adaptive immune systems. The dif-
ference between innate and adaptive immune responses
of the survivor and fatal CCHF patients need to be eluci-
dated to understand thoroughly the pathogenesis of
CCHF.
Additional files
Additional file 1: Correlation between serum interleukin-6 level (pg/mL)
at the time of admission and (A) C-reactive protein, (B) Prothrombin time
(C), Activated partial thromboplastin time, (D) International normalized ra-
tio, (E) Disseminated intravascular coagulation score, (F) Tumor necrosis
factor-alpha, and (G) Aspartate aminotransferase.
Additional file 2: Correlation between serum virus titer (copy/mL)
at the time of admission and (A) C-reactive protein, (B) Prothrombin
time (C), Activated partial thromboplastin time, (D) International
normalized ratio, (E) Disseminated intravascular coagulation score,
(F) Serum tumor necrosis factor-alpha, and (G) serum interleukin-6.
Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
Patients were followed and treated by SK, NE, AE, ID, MB, and MS. The
cytokine and anti-CCHFV Ig levels were studied by SK, NE, NG, MY, GK and
ZP. Sequential serum virus titers were studied by AK. The diagnostic tests
were performed by NY. NE performed the statistical analysis. SK and NE
wrote the article and review of the literature. TG, MGG, AE, MB, ID and MS
participated in the design of the study coordination and helped to draft the
manuscript. All authors read and approved the final manuscript.
Acknowledgments
We thank all of our patients and their relatives for their participation in the
study.
Author details
1Department of Infectious Diseases and Clinical Bacteriology, Training and
Research Hospital, Diyarbakir, Turkey. 2Department of Infectious Diseases and
Clinical Bacteriology, Faculty of Medicine, Cumhuriyet University, Sivas,
Turkey. 3Department of Clinical Microbiology, Section of Clinical Virology,
Gulhane Military Medicine Academy, Ankara, Turkey. 4Department of Food
Engineering, Faculty of Engineering, Cumhuriyet University, Sivas, Turkey.
5Cumhuriyet University Medical Faculty Research Center (CUTFAM),
Cumhuriyet University, Sivas, Turkey. 6Cumhuriyet University Vocabulary
School, Cumhuriyet University, Sivas, Turkey. 7Department of Virology, Refik
Saydam Hifzissiha Institute, Turkish Ministry of Health, Ankara, Turkey.
8Department of Internal Medicine, Section of Haematology, Faculty of
Medicine, Cumhuriyet University, Sivas, Turkey.
Kaya et al. BMC Infectious Diseases 2014, 14:416 Page 7 of 8
http://www.biomedcentral.com/1471-2334/14/416
Received: 1 February 2014 Accepted: 23 July 2014
Published: 28 July 2014
References
1. Whitehouse CA: Crimean-Congo hemorrhagic fever. Antiviral Res 2004,
64(3):145–160.
2. Elaldi N, Bodur H, Ascioglu S, Celikbas A, Ozkurt Z, Vahaboglu H,
Leblebicioglu H, Yilmaz N, Engin A, Sencan M, Aydin K, Dokmetas I, Cevik MA,
Dokuzoguz B, Tasyaran MA, Ozturk R, Bakir M, Uzun R: Efficacy of oral ribavirin
treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental
study from Turkey. J Infect 2009, 58(3):238–244.
3. Ergonul O: Crimean-Congo haemorrhagic fever. Lancet Infect Dis 2006,
6(4):203–214.
4. Gunes T, Engin A, Poyraz O, Elaldi N, Kaya S, Dokmetas I, Bakir M, Cinar Z:
Crimean-Congo hemorrhagic fever virus in high-risk population. Turkey
Emerg Infect Dis 2009, 15(3):461–464.
5. Geisbert TW, Jahrling PB: Exotic emerging viral diseases: progress and
challenges. Nat Med 2004, 10(12):110–121.
6. Schnittler HJ, Feldmann H: Viral Hemorrhagic fever-a vascular disease?
Thromb Haemost 2003, 89(6):967–972.
7. Burt FJ, Swanepoel R, Shieh WJ, Smith JF, Leman PA, Greer PW, Coffield LM,
Rollin PE, Ksiazek TG, Peters CJ, Zaki S: Immunohistochemical and in situ
localization of Crimean-Congo hemorrhagic fever (CCHF) virus in human
tissues and implications for CCHF pathogenesis. Arch Pathol Lab Med
1997, 121(8):839–846.
8. Joubert JR, King JB, Rossouw DJ, Cooper R: A nosocomial outbreak of
Crimean-Congo haemorrhagic fever at Tygerberg Hospital: Part III.
Clinical pathology and pathogenesis. S Afr Med J 1985, 68(10):722–728.
9. Papa A, Bino S, Velo E, Harxhi A, Kota M, Antoniadis A: Cytokine levels in
Crimean-Congo hemorrhagic fever. J Clin Virol 2006, 36(4):272–276.
10. Ergonul O, Tuncbilek S, Baykam N, Celikbas A, Dokuzoguz B: Evaluation of
serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha
in patients with Crimean-Congo hemorrhagic fever. J Infect Dis 2006, 193
(7):941–944.
11. Saksida A, Duh D, Wraber B, Dedushaj I, Ahmeti S, Avsic-Zupanc T: Interacting roles
of immune mechanisms and viral load in the pathogenesis of Crimean-Congo
hemorrhagic fever. Clin Vaccine Immunol 2010, 17(7):1086–1093.
12. Yapar M, Aydogan H, Pahsa A, Besirbellioglu BA, Bodur H, Basustaoglu AC,
Guney C, Avci IY, Sener K, Setteh MH, Kubar A: Rapid and quantitative
detection of Crimean-Congo hemorrhagic fever virus by one step Real-
Time Reverse Transcriptase-PCR. Jpn J Infect Dis 2005, 58(6):358–362.
13. Duh D, Saksida A, Petrovec M, Ahmeti S, Dedushaj I, Panning M, Drosten C,
Avsic-Zupanc T: Viral load as predictor of Crimean-Congo hemorrhagic
fever outcome. Emerg Infect Dis 2007, 13(11):1769–1772.
14. Cevik MA, Erbay A, Bodur H, Eren SS, Akinci E, Sener K, Ongürü P, Kubar A:
Viral load as a predictor of outcome in Crimean-Congo hemorrhagic
fever. Clin Infect Dis 2007, 45(7):e96–e100.
15. Wölfel R, Paweska JT, Petersen N, Grobbelaar AA, Leman PA, Hewson R,
Georges-Courbot MC, Papa A, Günther S, Drosten C: Virus detection and
monitoring of viral load in Crimean-Congo hemorrhagic fever virus
patients. Emerg Infect Dis 2007, 13(7):1097–1100.
16. Kubar A, Haciomeroglu M, Ozkul A, Bagriacik U, Akinci E, Sener K, Bodur H:
Prompt administration of Crimean-Congo hemorrhagic fever (CCHF)
virus hyperimmunoglobulin in patients diagnosed with CCHF and viral
load monitorization by reverse transcriptase-PCR. Jpn J Infect Dis 2011,
64(5):439–443.
17. Levi M, de Jonge E, Meijers J: The diagnosis of disseminated intravascular
coagulation. Blood Rev 2002, 16(4):217–223.
18. Swanepoel R, Gill DE, Shepherd AJ, Leman PA, Mynhardt JH, Harvey S: The
clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis
1989, 11(4):794–800.
19. Tignor GH, Hanham CA: Ribavirin efficacy in an in vivo model of
Crimean-Congo hemorrhagic fever virus (CCHF) infection. Antiviral Res
1993, 22(4):309–325.
20. Shepherd AJ, Swanepoel R, Leman PA: Antibody response in Crimean-Congo
hemorrhagic fever. Rev Infect Dis 1989, 11(4):801–806.
21. Akinci E, Bodur H, Leblebicioglu H: Pathogenesis of Crimean-Congo
hemorrhagic Fever. Vector Borne Zoonotic Dis 2013, 13(7):429–437.
22. Feldmann H, Bugany H, Mahner F, Klenk HD, Drenckhahn D, Schnittler HJ:
Filovirus-induced endothelial leakage triggered by infected monocytes/
macrophages. J Virol 1996, 70(4):2208–2214.
23. Papa A, Bino S, Llagami A, Brahimaj B, Papadimitriou E, Pavlidou V, Velo E,
Cahani G, Hajdini M, Pilaca A, Harxhi A, Antoniadis A: Crimean-Congo
hemorrhagic fever in Albania, 2001. Eur J Clin Microbiol Infect Dis 2002,
21(8):603–606.
24. Zelova H, Hosek J: TNF-α signalling and inflammation: interactions
between old acquaintances. Inflamm Res 2013, 62(7):641–651.
25. Levi M: Pathogenesis and treatment of disseminated intravascular
coagulation in the septic patient. J Crit Care 2001, 16(4):167–177.
26. Trotter L: Disseminated intravascular coagulation in the neonatal period.
Newborn and Infant Nursing Reviews 2004, 4(4):176–180.
27. Levi M, de Jonge E, van der Poll T: Plasma and plasma components in the
management of disseminated intravascular coagulation. Best Pract Res
Clin Haematol 2006, 19(1):127–142.
28. Mammen EF: Disseminated intravascular coagulation. Clin Lab Sci 2000,
13(4):239–245.
29. Libraty DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, Green S,
Vaughn DW, Nisalak A, Ennis FA, Rothman AL: High circulating levels of
the dengue virus nonstructural protein NS1 early in dengue illness
correlate with the development of dengue hemorrhagic fever. J Infect Dis
2002, 186(8):1165–1168.
30. Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, Nisalak A,
Rothman AL, Ennis FA: Elevated plasma IL-10 levels in acute dengue
correlate with disease severity. J Med Virol 1999, 59(3):329–334.
31. Villinger F, Rollin PE, Brar SS, Chikkala NF, Winter J, Sundstrom JB, Zaki SR,
Swanepoel R, Ansari AA, Peters CJ: Markedly elevated levels of interferon
(IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis
factor-alpha associated with fatal Ebola virus infection. J Infect Dis 1999,
179(Suppl1):S188–S191.
32. Kelso A: Cytokines: Principles and prospects. Immunol Cell Biol 1998,
76(4):300–317.
33. Andersson I, Karlberg H, Mousavi-Jazi M, Martínez-Sobrido L, Weber F, Mirazimi A:
Crimean-Congo hemorrhagic fever virus delays activation of the innate
immune response. J Med Virol 2008, 80(8):1397–1404.
34. Bereczky S, Lindegren G, Karlberg H, Akerström S, Klingström J, Mirazimi A:
Crimean-Congo hemorrhagic fever virus infection is lethal for adult type
I interferon receptor-knockout mice. J Gen Virol 2010, 91(Pt 6):1473–1477.
35. Zivcec M, Safronetz D, Scott D, Robertson S, Ebihara H, Feldmann H: Lethal
Crimean-Congo Hemorrhagic Fever virus infection in interferon α/β receptor
knockout mice is associated with high viral loads, pro-inflammatory
responses and coagulopathy. J Infect Dis 2013, 207(12):1909–1921.
doi:10.1186/1471-2334-14-416
Cite this article as: Kaya et al.: Sequential determination of serum viral
titers, virus-specific IgG antibodies, and TNF-α, IL-6, IL-10, and IFN-γ levels
in patients with Crimean-Congo hemorrhagic fever. BMC Infectious Diseases
2014 14:416.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kaya et al. BMC Infectious Diseases 2014, 14:416 Page 8 of 8
http://www.biomedcentral.com/1471-2334/14/416
